{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"1.22","upperLimit":"3.42","value":"1.57"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"The Progression-free survival (PFS) is defined as the time from registration to progression or death due to any cause. The distribution of PFS will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Phase I patients will receive the following treatment:\n\n* 250 mg/m\\^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle\n* 5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 1\n* 10 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8\n* CpG 7909 (Agatolimod Sodium) doses will be assigned in groups of 6 patients. Dose levels will escalate in each group until maximum tolerability is attained (starting at 0.08 mg/kg and sequentially escalating to 0.16 mg/kg, 0.32 mg/kg, 0.48 mg/kg). Doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.\n* 0.4 mCi/kg Yttrium-90 Zevalin IV on day 15","id":"OG000","title":"Phase I"},{"description":"Phase II patients will receive the following treatment:\n\n* 250 mg/m\\^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle\n* 5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8\n* 0.48 mg/kg CpG 7909 (Agatolimod Sodium) doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.\n* 0.4 mCi/kg Yttrium-90 Zevalin IV on day 15","id":"OG001","title":"Phase II"}],"paramType":"MEDIAN","populationDescription":"Only participants accrued to the Phase II portion of the study were evaluated for this endpoint.","reportingStatus":"POSTED","timeFrame":"Up to 1 year from treatment start date","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}